Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. QNTM
stocks logo

QNTM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for Quantum Biopharma Ltd (QNTM.O) is 0.00, compared to its 5-year average forward P/E of -1.71. For a more detailed relative valuation and DCF analysis to assess Quantum Biopharma Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.71
Current PE
0.00
Overvalued PE
0.94
Undervalued PE
-4.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.25
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.67
Undervalued EV/EBITDA
-1.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.07
Current PS
0.00
Overvalued PS
3.33
Undervalued PS
-1.19
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

QNTM News & Events

Events Timeline

(ET)
2025-12-01
07:17:00
Quantum Biopharma Files $700M Lawsuit Against CIBC and RBC for Market Manipulation
select
2025-11-07 (ET)
2025-11-07
07:07:39
Quantum BioPharma anticipates funding to extend past March 2027.
select
2025-11-07
07:06:12
Quantum BioPharma Announces Q3 Earnings Per Share of $1.25 Compared to ($4.37) Last Year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
11-28Newsfilter
Quantum BioPharma Files $700M Lawsuit Exposing Stock Spoofing Allegations
  • Massive Lawsuit Amount: Quantum BioPharma's $700 million lawsuit against CIBC and RBC alleges large-scale stock spoofing in the Canadian market, highlighting financial institutions' failures in market oversight, which could negatively impact the company's stock price.
  • Market Manipulation Phenomenon: CEO Zeeshan Saeed emphasizes that stock spoofing harms retail investors and may affect the company's future financing capabilities, exacerbating market instability and investor distrust.
  • Media Exposure Impact: The investigative series by CTV News provides significant public attention to Quantum BioPharma's lawsuit, potentially enhancing the company's transparency and trust among investors, which could positively influence shareholder confidence.
  • R&D Prospects: Quantum BioPharma is focused on developing Lucid-MS, a drug that has shown potential to reverse nerve cell degradation in animal studies, and if successful, it could create substantial market opportunities and societal value for the company.
[object Object]
Preview
7.0
11-28NASDAQ.COM
CTV W5 Investigates Quantum Biopharma's $700 Million Market Manipulation Case

  • Lawsuit Overview: Quantum BioPharma Ltd. has filed a $700 million lawsuit against major Canadian banks, alleging stock market manipulation that jeopardized its Lucid-MS research for multiple sclerosis, which has shown promising results in preclinical studies.

  • Impact on Investors: The company's stock price plummeted from $7.39 to under $2.76 between 2020 and 2021, causing significant losses for investors, including a 98% drop in value for some, which Quantum attributes to "spoofing" tactics on Canadian exchanges.

  • Regulatory Concerns: The lawsuit highlights potential failures by Canadian institutions to prevent market manipulation, with claims that over 16 million illegal orders originated from bank platforms, specifically naming CIBC and RBC as defendants.

  • Future of Lucid-MS: Despite financial challenges, Quantum is committed to advancing Lucid-MS and seeks damages to restore investor confidence and secure funding for clinical trials, emphasizing the critical nature of the lawsuit's outcome for ongoing research.

[object Object]
Preview
7.0
11-28Newsfilter
Quantum BioPharma Files $700M Lawsuit Uncovering Stock Manipulation
  • Massive Lawsuit Amount: Quantum BioPharma has filed a $700 million lawsuit against CIBC and RBC, alleging large-scale stock manipulation in the Canadian market, demonstrating the company's strong commitment to market integrity.
  • Market Manipulation Phenomenon: The company claims that Canadian trading data indicates at least 16 million illegal orders originated from these bank platforms, which not only affected its stock price but could also undermine long-term trust in the entire market.
  • Media Exposure Impact: The W5 investigative report by CTV News has raised public awareness of stock manipulation practices, potentially prompting regulators to enhance oversight of such activities in the market.
  • Drug Development Prospects: Quantum BioPharma is focused on developing the Lucid-MS drug, which has shown potential to reverse nerve cell degradation in animal studies, and if successful, could provide new hope for millions of multiple sclerosis patients.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Quantum Biopharma Ltd (QNTM) stock price today?

The current price of QNTM is 10 USD — it has increased 0.1 % in the last trading day.

arrow icon

What is Quantum Biopharma Ltd (QNTM)'s business?

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

arrow icon

What is the price predicton of QNTM Stock?

Wall Street analysts forecast QNTM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for QNTM is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Quantum Biopharma Ltd (QNTM)'s revenue for the last quarter?

Quantum Biopharma Ltd revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Quantum Biopharma Ltd (QNTM)'s earnings per share (EPS) for the last quarter?

Quantum Biopharma Ltd. EPS for the last quarter amounts to -1.40 USD, decreased -67.96 % YoY.

arrow icon

What changes have occurred in the market's expectations for Quantum Biopharma Ltd (QNTM)'s fundamentals?

The market is revising No Change the revenue expectations for Quantum BioPharma Ltd. (QNTM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -28.85%.
arrow icon

How many employees does Quantum Biopharma Ltd (QNTM). have?

Quantum Biopharma Ltd (QNTM) has 0 emplpoyees as of December 05 2025.

arrow icon

What is Quantum Biopharma Ltd (QNTM) market cap?

Today QNTM has the market capitalization of 38.17M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free